Affinity Asset Advisors, LLC Crinetics Pharmaceuticals, Inc. Transaction History
Affinity Asset Advisors, LLC
- $579 Million
- Q3 2024
A detailed history of Affinity Asset Advisors, LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Affinity Asset Advisors, LLC holds 400,000 shares of CRNX stock, worth $21.6 Million. This represents 3.53% of its overall portfolio holdings.
Number of Shares
400,000
Previous 515,000
22.33%
Holding current value
$21.6 Million
Previous $23.1 Million
11.42%
% of portfolio
3.53%
Previous 3.14%
Shares
5 transactions
Others Institutions Holding CRNX
# of Institutions
241Shares Held
79.5MCall Options Held
23.3KPut Options Held
44.3K-
Vanguard Group Inc Valley Forge, PA6.29MShares$339 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$336 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.89MShares$318 Million2.95% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.94MShares$267 Million0.03% of portfolio
-
Wellington Management Group LLP Boston, MA4.46MShares$241 Million0.04% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.9B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...